HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
NHC
National HealthCare Corporation
NHC's fundamentals are strong, but it looks expensive: trading at 29x earnings, above its usual 22x.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
NHC Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Stable |
NHC's profitability and cash flow are currently healthy, and its revenue and balance sheet are stable.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
NHC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 12x | $88.68 | -58% |
| Fair | 22x | $156 | -26% |
| Current | 29x | $211 | — |
| Expensive | 33x | $242 | +15% |
Historical ranges are pointers, not guarantees.
NHC's PE is in its expensive range at 29x.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
NHC Forward outlook
There aren't enough analyst estimates for NHC to show an outlook.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
NHC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $7.24 | +12% |
| Q2 2026 | $8.89 | +33% |
| Q1 2026 | $7.87 | +14% |
| Q4 2025 | $7.67 | +17% |
| Q3 2025 | $6.47 | -19% |
| Q2 2025 | $6.70 | +13% |
| Q1 2025 | $6.91 | +31% |
| Q4 2024 | $6.53 | +50% |
NHC has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over NHC on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
NHC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $408M | +6.6% |
| Q2 2026 | $408M | +8.8% |
| Q1 2026 | $381.8M | +2.2% |
| Q4 2025 | $386.5M | +4.6% |
| Q3 2025 | $382.7M | +12% |
| Q2 2025 | $374.9M | +25% |
| Q1 2025 | $373.7M | +26% |
| Q4 2024 | $369.4M | +23% |
NHC's revenue has grown year over year for 14 quarters in a row: $408M last quarter, up 6.6% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 10% | +2 points |
| Q2 2026 | 12% | +2.9 points |
| Q1 2026 | 8.4% | +0.2 points |
| Q4 2025 | 8.6% | +1.4 points |
| Q3 2025 | 7.9% | +1.8 points |
| Q2 2025 | 9.1% | +1.6 points |
| Q1 2025 | 8.2% | +3 points |
| Q4 2024 | 7.2% | +0.5 points |
NHC has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over NHC on cash flow, with more consistent year-over-year improvement.
NHC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $99.2M | +76% |
| Q2 2026 | $30.7M | -42% |
| Q1 2026 | $52.9M | +60% |
| Q4 2025 | $6.4M | +38% |
| Q3 2025 | $56.5M | +98% |
| Q2 2025 | $52.6M | +23% |
| Q1 2025 | $33.1M | +797% |
| Q4 2024 | $4.6M | -73% |
NHC generated $189M in free cash flow over the past year, up 29% from the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over NHC on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
NHC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.6% | +101K shares |
| 1 year | +1.9% | +300K shares |
| 3 years | +4.2% | +640K shares |
| 5 years | +3.9% | +601K shares |
| Available history | +3.9% | +605K shares |
NHC has 16M diluted shares, up 1.9% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $1.1M |
| Q2 2026 | $7.2M |
| Q1 2026 | $16.3M |
| Q4 2025 | $5.2M |
| Q3 2025 | $3.2M |
| Q2 2025 | $4.7M |
| Q1 2025 | $1.7M |
| Q4 2024 | — |
NHC spent $30M buying back its own shares over the past year, about three times what it spent the year before.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
NHC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.1x | Moderate |
| Q2 2026 | -0.2x | Net Cash |
| Q1 2026 | -0.5x | Net Cash |
| Q4 2025 | -0.3x | Net Cash |
| Q3 2025 | -0.4x | Net Cash |
| Q2 2025 | -0.0x | Net Cash |
| Q1 2025 | 0.3x | Very low |
| Q4 2024 | 0.5x | Very low |
NHC's net debt is about 2.1 years of its operating earnings (EBITDA), after holding more cash than debt a year ago.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
NHC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 50.0 | Neutral |
| Stochastic | 15.5 | Oversold |
NHC's weekly RSI is 50 (neutral) and its Stochastic is 15 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
NHC PE vs Healthcare Sector
| Metric | NHC | Sector median | Relative |
|---|---|---|---|
| PE | 29x | 26x | 13% above |
| PE % | 73 | 29 | 44 pts above |
NHC is trading at 29x earnings, a 13% premium to the Healthcare sector's median of 26x.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
NHC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $223.3 | 5.6% below |
| 20 week MA | $222.8 | 5.4% below |
| 50 week MA | $188.1 | 12% above |
| 100 week MA | $147.3 | 43% above |
| 200 week MA | $117.5 | 79% above |
NHC has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
NHC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $85.0 | $66.3 | -22% |
| 2021 | $66.3 | $67.7 | +2.2% |
| 2022 | $67.7 | $61.8 | -8.8% |
| 2023 | $61.8 | $92.4 | +50% |
| 2024 | $92.4 | $109.6 | +19% |
| 2025 | $109.6 | $138.7 | +27% |
| 2026 YTD | $138.7 | $210.8 | +52% |
NHC has the edge over HIMS on returns for 2026, with the stronger performance.